A Phase 1/2a Open-label Trial to Evaluate the Safety, Tolerability, PK, PD, Immunogenicity, and Antitumor Activity of LAVA-1207, a PSMA-targeting Bispecific γδ-T Cell Engager, Alone or With Low Dose Interleukin-2 or Pembrolizumab, in Patients With Therapy Refractory mCRPC
Latest Information Update: 05 Jul 2024
At a glance
- Drugs LAVA-1207 (Primary) ; Pembrolizumab
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man
- Acronyms KEYNOTE-F73
- Sponsors Lava Therapeutics
- 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 21 May 2024 According to a Lava Therapeutics media release, the company is expecting to enroll the first patient in Q2 2024 in the LAVA-1207 + pembrolizumab dose-escalation arm
- 21 May 2024 According to a Lava Therapeutics media release, the company look forward to sharing an update on the LAVA-1207 program during the second half of 2024